GlaxoSmithKline (GSK) today announced it has submitted applications for both U.S. and European marketing approval for a new medicine to treat thesymptoms of seasonal allergic rhinitis (SAR) and perennial allergicrhinitis (PAR). The medicine (fluticasone furoate) is an enhanced affinityintranasal corticosteroid with the proposed name of ALLERMIST in the U.S.and AVAMYS in Europe. [click link for full article]
(more...)